Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis

References

• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–2515. doi: 10.1182/blood-2007-07-102798
   PubMed Web of Science ®Google Scholar
• Ferrara F. Acute promyelocytic leukemia: what are the treatment options? Expert Opin Pharmacother. 2010;11(4):587–596. doi: 10.1517/14656560903505115
   PubMed Web of Science ®Google Scholar
• Zhou GB, Zhao WL, Wang ZY, et al. Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med. 2005;2:e12. doi: 10.1371/journal.pmed.0020012
   PubMed Web of Science ®Google Scholar
• Asou N, Adachi K, Tamura U, et al. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 2001;48:S65–71. doi: 10.1007/s002800100308
   PubMed Web of Science ®Google Scholar
• Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 1992;79:543–53.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Mele A, Stazi MA, et al. Epidemiology of acute promyelocytic leukemia in Italy. Ann Oncol. 1991;2:405–411. doi: 10.1093/oxfordjournals.annonc.a057974
   PubMed Web of Science ®Google Scholar
• Rees D, Grimwade D, Langabeer S, et al. Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. MRC Adult Leukaemia Working Party. Br J Haematol. 1997;96(3):490–2. doi: 10.1046/j.1365-2141.1997.d01-2063.x
   PubMed Web of Science ®Google Scholar
• Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16(3):463–82. doi: 10.1016/S1521-6926(03)00059-8
   PubMed Web of Science ®Google Scholar
• Douer D, Preston-Martin S, Chang E, et al. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996;87(1):308–13.
   PubMed Web of Science ®Google Scholar
• Thuler LC, Pombo-de-Oliveira MS. Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012. Ann Hematol. 2017;96(3):355–62. doi: 10.1007/s00277-016-2846-0
   PubMed Web of Science ®Google Scholar
• Ades L, Chevret S, De Botton S, et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005;19(2):230–3. doi: 10.1038/sj.leu.2403597
   PubMed Web of Science ®Google Scholar
• Zhang L, Samad A, Pombo-de-Oliveira MS, et al. Global characteristics of childhood acute promyelocytic leukemia. Blood Rev. 2015;29(2):101–25. doi: 10.1016/j.blre.2014.09.013
   PubMed Web of Science ®Google Scholar
• Drapkin RL, Gee TS, Dowling MD, et al. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer. 1978;41(6):2484–90. doi: 10.1002/1097-0142(197806)41:6<2484::AID-CNCR2820410659>3.0.CO;2-#
   PubMed Web of Science ®Google Scholar
• Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41(4):489–96.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Avvisati G, Castaman G, et al. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75(11):2112–7.
   PubMed Web of Science ®Google Scholar
• Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood. 1995;86(5):1717–28.
   PubMed Web of Science ®Google Scholar
• Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567–72.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021–8. doi: 10.1056/NEJM199710093371501
   PubMed Web of Science ®Google Scholar
• Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015;5:e304. doi: 10.1038/bcj.2015.25
   PubMed Web of Science ®Google Scholar
• Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): acomparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111:1078–84. doi: 10.1182/blood-2007-07-099978
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. http://handbook.cochrane.org/.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006;24(36):5703–10. doi: 10.1200/JCO.2006.08.1596
   PubMed Web of Science ®Google Scholar
• Adès L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115(9):1690–6. doi: 10.1182/blood-2009-07-233387
   PubMed Web of Science ®Google Scholar
• Asou N, Adachi K, Tamura J, et al. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 1997;40(Suppl.):S30–e15. doi: 10.1007/s002800051058
   PubMed Web of Science ®Google Scholar
• Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59–66. doi: 10.1182/blood-2006-08-043992
   PubMed Web of Science ®Google Scholar
• Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996;88(4):1390–1398.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Grimwade D, et al. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia. 2013;27(4):843–851. doi: 10.1038/leu.2012.360
   PubMed Web of Science ®Google Scholar
• Colovic MD, Jankovic GM, Elezovic I, et al. Effect of all-trans-retinoic add alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia. Med Oncol. 1997;14:65–72. doi: 10.1007/BF02990950
   PubMed Web of Science ®Google Scholar
• de Botton S, Coiteux V, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2004;22(8):1404–1412. doi: 10.1200/JCO.2004.09.008
   PubMed Web of Science ®Google Scholar
• Diverio D, Rossi V, Avvisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial. GIMEMA-AIEOP Multicenter “AIDA” Trial. Blood. 1998;92(3):784–789.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94(4):1192–1200.
   PubMed Web of Science ®Google Scholar
• Huang H, Qin Y, Xu R, et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leuk Res. 2012;36(7):841–845. doi: 10.1016/j.leukres.2012.03.027
   PubMed Web of Science ®Google Scholar
• Iland H, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012;97(2):227–234. doi: 10.3324/haematol.2011.047506
   PubMed Web of Science ®Google Scholar
• Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood. 1995;85(5):1202–1206.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Miyawaki S, Tanimoto M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/ intensification therapy in adult acute myeloid leukemia. J Clin Oncol. 1996;14:204–209. doi: 10.1200/JCO.1996.14.1.204
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fazi P, et al. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011;154(5):564–568. doi: 10.1111/j.1365-2141.2011.08593.x
   PubMed Web of Science ®Google Scholar
• Leech M, Morris L, Stewart M, et al. Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy. Clin Lymphoma Myeloma Leuk. 2015;15(5):292–297. doi: 10.1016/j.clml.2014.11.001
   PubMed Web of Science ®Google Scholar
• Liu YJ, Wu DP, Liang JY, et al. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients. Med Oncol. 2011;28(1):S513–S521. doi: 10.1007/s12032-010-9733-7
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171–3179. doi: 10.1182/blood-2010-03-276196
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121. doi: 10.1056/NEJMoa1300874
   PubMed Web of Science ®Google Scholar
• Long ZJ, Hu Y, Li XD, et al. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia. PLoS One. 2014;9(8):e104610). doi: 10.1371/journal.pone.0104610
   PubMed Web of Science ®Google Scholar
• Lou Y, Qian q, Meng H, et al. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leukemia Res. 2013;37(1):37–42. doi: 10.1016/j.leukres.2012.09.004
   PubMed Web of Science ®Google Scholar
• Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90(3):1014–1021.
   PubMed Web of Science ®Google Scholar
• Mann G, Reinhardt D, Ritter J, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol. 2001;80(7):417–422. doi: 10.1007/s002770100304
   PubMed Web of Science ®Google Scholar
• Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315–3324.
   PubMed Web of Science ®Google Scholar
• Ohno R, Kobayashi T, Tanimoto M, et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. Cancer. 1993;71:3888–3894. doi: 10.1002/1097-0142(19930615)71:12<3888::AID-CNCR2820711216>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Ortega JJ, Madero L, Martín G, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol. 2005;23(30):7632–7640. doi: 10.1200/JCO.2005.01.3359
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751–3757. doi: 10.1182/blood-2010-02-269621
   PubMed Web of Science ®Google Scholar
• Sanz MA, Martín G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237–1243. doi: 10.1182/blood-2003-07-2462
   PubMed Web of Science ®Google Scholar
• Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR alpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94(9):3015–3021.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):5137–5146. doi: 10.1182/blood-2010-01-266007
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008;112(8):3130–3134. doi: 10.1182/blood-2008-05-159632
   PubMed Web of Science ®Google Scholar
• Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101(15):5328–5335. doi: 10.1073/pnas.0400053101
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100(13):4298–4302. doi: 10.1182/blood-2002-02-0632
   PubMed Web of Science ®Google Scholar
• Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106(2):447–453. doi: 10.1182/blood-2004-05-1971
   PubMed Web of Science ®Google Scholar
• Xiang-Xin L, Lu-Qun W, Hao L, et al. Clinical study on prospective efficacy of all-trans acid, realgar-indigo naturalis formula combined with chemotherapy as maintenance treatment of acute promyelocytic leukemia. Evid Based Complement Alternat Med. 2014;2014:987560. doi: 10.1155/2014/987560
   PubMed Web of Science ®Google Scholar
• Xin L, Wan-jun S, Zeng-jun L, et al. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center. Leuk Res. 2007;31(6):765–771. doi: 10.1016/j.leukres.2006.07.028
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu D, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215–4222. doi: 10.1200/JCO.2013.48.8312
   PubMed Web of Science ®Google Scholar
• Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007;20:57–65. doi: 10.1016/j.beha.2006.11.002
   PubMed Web of Science ®Google Scholar
• Fenaux P, Pollet J, Vandenbossche L, et al. Treatment of acute promyelocytic leukemia: a report on 70 cases. Leuk Lymphoma. 1991a;4:249–253. doi: 10.3109/10428199109068072
   PubMed Web of Science ®Google Scholar
• Fenaux P, Tertian G, Castaigne S, et al. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J Clin Oncol. 1991b;9:1556–1561. doi: 10.1200/JCO.1991.9.9.1556
   PubMed Web of Science ®Google Scholar
• Casazza AM, Pratesi G, Giuliani F, et al. Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumor. 1980;66:549–564.
   PubMed Web of Science ®Google Scholar
• Thomas X, Le Q, Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann Hematol. 2002;81:504–507. doi: 10.1007/s00277-002-0534-8
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Kornblau S, et al. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia. 2002;16:1888–1893. doi: 10.1038/sj.leu.2402616
   PubMed Web of Science ®Google Scholar
• Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol. 2000;108(4):689–695. doi: 10.1046/j.1365-2141.2000.01936.x
   PubMed Web of Science ®Google Scholar
• Park J, Jurcic JG, Rosenblat T, et al. Emerging new approaches for the treatment of acute promyelocytic leukemia. Ther Adv Hematol. 2011;2(5):335–352. doi: 10.1177/2040620711410773
   PubMedGoogle Scholar
• Zhou GB, Zhang J, Wang ZY, et al. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci. 2007;362:959–971. doi: 10.1098/rstb.2007.2026
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–1253.
   PubMed Web of Science ®Google Scholar
• De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92(8):2712–2718.
   PubMed Web of Science ®Google Scholar
• Lou Y, Ma Y, Suo S, et al. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy. Leuk Res. 2015;39(9):938–944. doi: 10.1016/j.leukres.2015.05.016
   PubMed Web of Science ®Google Scholar
• Rego EM, Kim HT, Ruiz-Argüelles GJ, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013;121(11):1935–1943. doi: 10.1182/blood-2012-08-449918
   PubMed Web of Science ®Google Scholar
• Baljevic M, Park JH, Stein E, et al. Curing all patients with acute promyelocytic leukemia: are we there yet? Hematol Oncol Clin North Am. 2011;25(6):1215–1233. doi: 10.1016/j.hoc.2011.10.002
   PubMed Web of Science ®Google Scholar